STAAR Surgical (NASDAQ:STAA) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. trimmed its position in STAAR Surgical (NASDAQ:STAA - Free Report) by 22.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 166,648 shares of the medical instruments supplier's stock after selling 48,102 shares during the period. JPMorgan Chase & Co. owned 0.34% of STAAR Surgical worth $4,048,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new stake in shares of STAAR Surgical during the 4th quarter valued at about $180,000. Quantbot Technologies LP acquired a new position in STAAR Surgical in the fourth quarter valued at approximately $278,000. Y Intercept Hong Kong Ltd acquired a new position in STAAR Surgical in the fourth quarter valued at approximately $292,000. Counterpoint Mutual Funds LLC bought a new stake in shares of STAAR Surgical in the 4th quarter worth approximately $298,000. Finally, HighTower Advisors LLC boosted its position in STAAR Surgical by 42.6% during the 4th quarter. HighTower Advisors LLC now owns 12,956 shares of the medical instruments supplier's stock valued at $315,000 after purchasing an additional 3,871 shares during the period. 96.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Canaccord Genuity Group dropped their target price on STAAR Surgical from $28.00 to $17.00 and set a "hold" rating on the stock in a research report on Thursday, February 13th. BTIG Research cut shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a report on Wednesday, February 12th. StockNews.com lowered shares of STAAR Surgical from a "hold" rating to a "sell" rating in a research note on Thursday, February 13th. Stephens restated an "equal weight" rating and issued a $17.00 price target on shares of STAAR Surgical in a research note on Tuesday, March 18th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of STAAR Surgical in a research report on Thursday, February 27th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $24.25.

Insider Transactions at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 497,631 shares of the stock in a transaction dated Friday, April 4th. The shares were bought at an average price of $15.91 per share, with a total value of $7,917,309.21. Following the purchase, the insider now directly owns 13,194,210 shares of the company's stock, valued at approximately $209,919,881.10. This trade represents a 3.92 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have bought 1,742,581 shares of company stock valued at $28,407,543. Corporate insiders own 1.00% of the company's stock.

STAAR Surgical Stock Down 2.0 %

STAA traded down $0.35 during trading on Friday, reaching $17.53. The stock had a trading volume of 65,015 shares, compared to its average volume of 791,574. The firm has a market capitalization of $864.47 million, a price-to-earnings ratio of -42.77 and a beta of 0.75. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $49.86. The stock has a 50 day moving average of $17.19 and a two-hundred day moving average of $22.94.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.